172 related articles for article (PubMed ID: 14689466)
1. Rapid determination of enzyme activities of recombinant human cytochromes P450, human liver microsomes and hepatocytes.
Ghosal A; Hapangama N; Yuan Y; Lu X; Horne D; Patrick JE; Zbaida S
Biopharm Drug Dispos; 2003 Dec; 24(9):375-84. PubMed ID: 14689466
[TBL] [Abstract][Full Text] [Related]
2. Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes.
Donato MT; Jiménez N; Castell JV; Gómez-Lechón MJ
Drug Metab Dispos; 2004 Jul; 32(7):699-706. PubMed ID: 15205384
[TBL] [Abstract][Full Text] [Related]
3. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes.
Parkinson A; Mudra DR; Johnson C; Dwyer A; Carroll KM
Toxicol Appl Pharmacol; 2004 Sep; 199(3):193-209. PubMed ID: 15364537
[TBL] [Abstract][Full Text] [Related]
4. Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine.
Arbus C; Benyamina A; Llorca PM; Baylé F; Bromet N; Massiere F; Garay RP; Hameg A
Eur J Pharm Sci; 2007 Dec; 32(4-5):357-66. PubMed ID: 17951033
[TBL] [Abstract][Full Text] [Related]
5. Roles of NADPH-P450 reductase and apo- and holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli.
Yamazaki H; Nakamura M; Komatsu T; Ohyama K; Hatanaka N; Asahi S; Shimada N; Guengerich FP; Shimada T; Nakajima M; Yokoi T
Protein Expr Purif; 2002 Apr; 24(3):329-37. PubMed ID: 11922748
[TBL] [Abstract][Full Text] [Related]
6. The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro.
Muschler E; Lal J; Jetter A; Rattay A; Zanger U; Zadoyan G; Fuhr U; Kirchheiner J
Basic Clin Pharmacol Toxicol; 2009 Dec; 105(6):374-9. PubMed ID: 19614891
[TBL] [Abstract][Full Text] [Related]
7. In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes.
Fang J; McKay G; Song J; Remillrd A; Li X; Midha K
Drug Metab Dispos; 2001 Dec; 29(12):1638-43. PubMed ID: 11717183
[TBL] [Abstract][Full Text] [Related]
8. Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes.
Ono S; Hatanaka T; Hotta H; Satoh T; Gonzalez FJ; Tsutsui M
Xenobiotica; 1996 Jul; 26(7):681-93. PubMed ID: 8819299
[TBL] [Abstract][Full Text] [Related]
9. Effects of cytochrome P450 inhibitors on the biotransformation of fluorogenic substrates by adult male rat liver microsomes and cDNA-expressed rat cytochrome P450 isoforms.
Makaji E; Trambitas CS; Shen P; Holloway AC; Crankshaw DJ
Toxicol Sci; 2010 Feb; 113(2):293-304. PubMed ID: 19858067
[TBL] [Abstract][Full Text] [Related]
10. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil.
Robertson P; DeCory HH; Madan A; Parkinson A
Drug Metab Dispos; 2000 Jun; 28(6):664-71. PubMed ID: 10820139
[TBL] [Abstract][Full Text] [Related]
11. Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes.
Shimada T; Tsumura F; Yamazaki H
Drug Metab Dispos; 1999 Nov; 27(11):1274-80. PubMed ID: 10534312
[TBL] [Abstract][Full Text] [Related]
12. Effect of acetylcholinesterase oxime-type reactivators K-48 and HI-6 on human liver microsomal cytochromes P450 in vitro.
Veinlichova A; Jancova P; Siller M; Anzenbacher P; Kuca K; Jun D; Fusek J; Anzenbacherova E
Chem Biol Interact; 2009 Aug; 180(3):449-53. PubMed ID: 19539805
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450-mediated metabolism of triclosan attenuates its cytotoxicity in hepatic cells.
Wu Y; Chitranshi P; Loukotková L; Gamboa da Costa G; Beland FA; Zhang J; Fang JL
Arch Toxicol; 2017 Jun; 91(6):2405-2423. PubMed ID: 27896399
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction.
Kumar G; Lau H; Laskin O
Cancer Chemother Pharmacol; 2009 May; 63(6):1171-5. PubMed ID: 19030860
[TBL] [Abstract][Full Text] [Related]
15. Functional expression, inhibition and induction of CYP enzymes in HepaRG cells.
Turpeinen M; Tolonen A; Chesne C; Guillouzo A; Uusitalo J; Pelkonen O
Toxicol In Vitro; 2009 Jun; 23(4):748-53. PubMed ID: 19328226
[TBL] [Abstract][Full Text] [Related]
16. Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay.
Turpeinen M; Uusitalo J; Jalonen J; Pelkonen O
Eur J Pharm Sci; 2005 Jan; 24(1):123-32. PubMed ID: 15626586
[TBL] [Abstract][Full Text] [Related]
17. Validated assays for human cytochrome P450 activities.
Walsky RL; Obach RS
Drug Metab Dispos; 2004 Jun; 32(6):647-60. PubMed ID: 15155557
[TBL] [Abstract][Full Text] [Related]
18. The use of 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC) as a specific CYP2D6 probe in human liver microsomes.
Chauret N; Dobbs B; Lackman RL; Bateman K; Nicoll-Griffith DA; Stresser DM; Ackermann JM; Turner SD; Miller VP; Crespi CL
Drug Metab Dispos; 2001 Sep; 29(9):1196-200. PubMed ID: 11502727
[TBL] [Abstract][Full Text] [Related]
19. The olivacine derivative s 16020 (9-hydroxy-5,6-dimethyl-N-[2-(dimethylamino)ethyl)-6H-pyrido(4,3-B)-carbazole-1-carboxamide) induces CYP1A and its own metabolism in human hepatocytes in primary culture.
Pichard-Garcia L; Weaver RJ; Eckett N; Scarfe G; Fabre JM; Lucas C; Maurel P
Drug Metab Dispos; 2004 Jan; 32(1):80-8. PubMed ID: 14709624
[TBL] [Abstract][Full Text] [Related]
20. Distinction between human cytochrome P450 (CYP) isoforms and identification of new phosphorylation sites by mass spectrometry.
Redlich G; Zanger UM; Riedmaier S; Bache N; Giessing AB; Eisenacher M; Stephan C; Meyer HE; Jensen ON; Marcus K
J Proteome Res; 2008 Nov; 7(11):4678-88. PubMed ID: 18828626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
